Lexeo Therapeutics, Inc. filings document a clinical-stage cardiovascular genetic medicine company and its formal disclosures on operations, pipeline progress, governance, and capital resources. Recent 8-K reports furnish financial results, business highlights, corporate presentations, and clinical updates for AAV gene therapy programs including LX2006 and LX2020.
The company’s SEC record also covers Regulation FD materials, CMC and regulatory-update disclosures, leadership transitions, director appointments, compensatory arrangements, and proxy matters for annual stockholder meetings. Its definitive proxy statement addresses board service, committee structure, voting proposals, executive compensation, and other governance information relevant to Lexeo’s public-company oversight.
Lexeo Therapeutics Schedule 13G/A Amendment No. 2 reports beneficial ownership disclosures by Paradigm-related reporting persons as of the close of business on March 31, 2026. Paradigm BioCapital Advisors (and affiliated entities) report 6,184,134 shares (8.3%) and Paradigm BioCapital International Fund Ltd. reports 5,449,272 shares (7.4%). The filing states the ownership percentages are calculated using 74,086,737 shares outstanding as of March 31, 2026.
Lexeo Therapeutics, Inc. Schedule 13G/A reports that Balyasny Asset Management and related entities beneficially own 7,176,144 shares of Common Stock, representing 9.69% of the class. The filing states this position includes 5,586,529 shares issuable upon exercise of warrants subject to a "Beneficial Ownership Limitation," and cites 74,087,063 shares outstanding as of March 27, 2026.
The filing lists voting and dispositive authority as sole for the reported shares and identifies the reporting persons as Balyasny Asset Management L.P., BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny. ADMF and APHC are named as the direct holders on whose behalf the reporting persons report ownership.
Lexeo Therapeutics’ quarterly report shows a smaller loss and a solid cash position as it advances gene therapy programs for cardiovascular disease. For the three months ended March 31, 2026, net loss was $20.2 million, improved from $32.7 million a year earlier, as operating expenses fell to $22.3 million from $33.8 million.
The company reported cash, cash equivalents and investments in U.S. Treasury securities of $227.6 million and total assets of $250.4 million, with an accumulated deficit of $400.3 million. Management believes this cash balance will fund operations for at least 12 months, though additional capital will be needed longer term.
Lexeo Therapeutics reported first quarter 2026 results alongside detailed pipeline updates in an 8-K and investor presentation. The company posted a net loss of $20.2 million, or $0.25 per share, an improvement from a $32.7 million loss a year earlier, driven partly by sharply lower general and administrative expenses.
Cash, cash equivalents and marketable securities were $227.6 million as of March 31, 2026, which Lexeo believes will fund operations into 2028. The update highlights progress for lead cardiac gene therapy programs LX2006 in Friedreich ataxia cardiomyopathy and LX2020 in PKP2 arrhythmogenic cardiomyopathy, including ongoing pivotal‑trial preparations and additional clinical data, and notes a new independent director appointment.
Lexeo Therapeutics, Inc. director Laura Sepp-Lorenzino received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $5.81 per share and expire on April 27, 2036. They vest in equal annual installments over three years, so the award becomes fully exercisable on the third anniversary of the grant date, subject to her continuous service with the company. After this grant, she holds options for 50,000 underlying shares directly.
Lexeo Therapeutics, Inc. director Laura Sepp-Lorenzino has filed a Form 3 insider ownership report. The provided data lists her status as a director of the company and shows no reported transactions, share holdings, or derivative securities in this filing excerpt.
Lexeo Therapeutics, Inc. is holding a fully virtual 2026 annual stockholders meeting on June 25, 2026, at 10:00 a.m. Eastern via www.virtualshareholdermeeting.com/LXEO2026. Stockholders will vote on electing three Class III directors to terms running to the 2029 annual meeting and on ratifying KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Holders of common stock as of the May 7, 2026 record date, with one vote per share, may vote online, by phone, mail, or during the webcast. There were 78,520,587 shares of common stock outstanding as of April 24, 2026. The board recommends voting FOR all director nominees and FOR auditor ratification. The proxy also details board committee structure, director independence, non-employee director fees and option grants, and executive pay, including salaries, equity awards, and change-in-control severance terms for senior leaders.
Lexeo Therapeutics, Inc. appointed Dr. Laura Sepp-Lorenzino to its board of directors effective April 28, 2026. She will serve until the company’s 2028 annual meeting of stockholders and has also been named to the company’s Science and Technology Committee.
Dr. Sepp-Lorenzino brings extensive experience from leadership and scientific roles at multiple biotechnology and pharmaceutical companies and currently leads a consulting firm focused on genomic medicine. Under Lexeo’s non-employee director compensation policy, she will receive $40,000 in annual cash compensation and an initial option to purchase 50,000 shares, with future annual option grants of 25,000 shares beginning with the 2027 annual meeting.
Lexeo Therapeutics ownership disclosure: Suvretta Capital Management, LLC reports shared beneficial ownership of 5,674,778 shares (7.7%) of common stock, and Averill Master Fund, Ltd. reports shared beneficial ownership of 4,827,730 shares (6.5%). Aaron Cowen is reported with shared beneficial ownership of 5,674,778 shares (7.7%). The schedule states these securities are directly owned by advisory clients of Suvretta and includes a joint filing agreement and control-person identification.